linjc16/ctgov huggingface dataset:
Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects

Study Overview
=================
Brief Summary
-----------------
Aim of this study is to enhance the knowledge of myogenic tone alterations in hypertensive patients and to better understand the mechanisms controlling the myogenic tone. Evaluations will be performed through ex vivo studies of peripheral arterioles in human adipose tissue from lumbar muscle, isolated from biopsies. This will allow investigators to evaluate the myogenic function in response to progressive blood pressure increases, in order to correlate myogenic function to arterial hypertension and to the molecular mechanisms already identified in the preclinical models.

Official Title
-----------------
Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females between 30 and 70 years of age Hypertensive patients: Patients with a previous diagnosis of hypertension Normotensive patients: subjects without story of hypertension Written informed consent Exclusion Criteria: Severe hypertension (eg, systolic >180 mm Hg, diastolic >110 mm Hg) Manifested or suspected secondary hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, pheochromocytoma) History of cardiac complications (previous acute myocardial infarction (AMI), unstabile angina, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG), congestive heart failure (NYHA II-IV)) Diabetes mellitus Renal pathologies (creatinine clearance < 30 ml/min) Severe hepatic dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Case<br>Hypertensive subjects | |
| Control<br>Normotensive subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Myogenic tone measured by micromyographic technique to evaluate small-artery morphology. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, myogenic tone
Documentation of Cardiac Arrhythmias After Open Heart Surgery

Study Overview
=================
Brief Summary
-----------------
This study aims at recording cardiac arrhythmias in patients after open heart surgery. The arrhythmias will be monitored during the entire first postoperative period, till six weeks after surgery.

Detailed Description
-----------------
Approximately 30-50% of patients after cardiac surgery develop cardiac arrhythmias, most often atrial, and most frequently atrial fibrillation (AF). Various risk factors, inter alia, the type of surgery itself are risk factors. The major additional risk factors for postoperative atrial fibrillation are: age, valvular involvement, length of cardiopulmonary bypass and cross-clamp times. Postoperative atrial fibrillation is associated with increased length of stay, higher morbidity and mortality including stroke. Documentation of postopertive atrial fibrillation is well gathered during the postopertive length of stay, but scarce information exists regarding the development and occurence of atrial arrhythmias after the patient's discharge. Additionally, the various management protocols which exists with regard to postoperative atrial fibrillation, rely on continuous treatment of the patients with amiodarone or various other anti-arrhythmic agents for the initial postoperative period, and the initial first month after discharge. So far there is not an unambiguous recommendation regarding the duration of treatment required with amiodarone after releasing the patient. The aim of this study is to document and record cardiac arrhythmias in patients after open-heart surgery within the time window since the release from hospital and up to six weeks after surgery. Results of the study will allow us to fully characterize postoperative arrhythmias and their risk factors.

Official Title
-----------------
Documentation of Cardiac Arrhythmias After Open Heart Surgery

Conditions
-----------------
Cardiac Arrhythmias

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older. Patients after open-heart surgery (any type of surgery). Exclusion Criteria: Patients with internal pacemaker. patients with known basic arrhythmia (pre-surgery) or patients who are discharged with some arrhythmias. Patients with low response which it is expected that there will not be able to use the monitoring device

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arrhythmia | Documention of arrhythmias in patients after open heart surgery during the six (6) weeks after release | 6 weeks |
Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery

Study Overview
=================
Brief Summary
-----------------
This pilot clinical trial studies ultrasound imaging in finding prostate cancer in patients undergoing surgery. Diagnostic procedures, such as ultrasound imaging, may help find and diagnose prostate cancer. This study will serve as an analysis of the Histo-Scanning technology for the purpose of determining its ability to identify sites of prostate cancer at the time of prostate ultrasound.

Official Title
-----------------
A Pilot Evaluation of the Efficacy of HistoScanning™ in Predicting the Presence and Location of Prostate Cancer in Men Undergoing Radical Prostatectomy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Procedure: Ultrasound Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have completed a staging multiparametric MRI at New York University (NYU) Patients who plan to undergo radical prostatectomy by open or robotic approach Exclusion Criteria: Previous History of Prostate Cancer Radiation Treatment Focal Ablation of the prostate for cancer treatment Men receiving hormonal ablation within 6 months prior to undergoing radical prostatectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ultrasound Imaging<br>Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure. | Procedure: Ultrasound Imaging<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Histoscan findings with Radical Prostatectomy Pathology | Compare location and concordance of findings on pre-op MRI & Histoscan with radical prostatectomy specimen | up to 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extent of tumor and grade in treatment planning | Describe correlation between tumor grade on final pathology and histoscan findings | Up to 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate Cancer, Radical Prostatectomy, Ultrasound Imaging
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Study Overview
=================
Brief Summary
-----------------
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

Detailed Description
-----------------
This is an open-label, multicenter study of oral TR-701 FA 200 mg once daily for 6 days for the treatment of major cutaneous abscess or cellulitis/erysipelas in patients 18 years of age or older. This study is designed to further characterize the safety profile and gather additional lesion measurement data of TR-701 FA in patients with major cutaneous abscess or cellulitis/erysipelas.

Official Title
-----------------
Phase 2 Open-Label Safety and Exploratory Skin Lesion Measurement Study of 6-Day Oral TR-701 FA in Skin Abscess and Cellulitis Patients

Conditions
-----------------
Cellulitis, Major Cutaneous Abscess, Erysipelas

Intervention / Treatment
-----------------
* Drug: TR701 FA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients ≥ 18 years of age Suspected or documented gram-positive infection from baseline Gram stain or culture. Cellulitis/erysipelas or major cutaneous abscesses at Screening Exclusion Criteria: Postsurgical or open wound infections Severe sepsis or septic shock Uncomplicated skin and skin structure infections such as furuncles, minor abscesses (< 75 cm2 or area of suppuration not surrounded by cellulitis/erythema), and impetiginous lesions Infections associated with, or in close proximity to, a prosthetic device Known bacteremia or osteomyelitis at time of screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TR-701 FA<br> | Drug: TR701 FA<br>* 1 tablet 200 mg once daily<br>* Other names: Tedizolid;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Safety will be assessed through summaries of the incidence of AEs and SAEs as well as through summaries of vital signs, physical examinations, ECG findings, and laboratory assessments (hematology, serum chemistry, and urinalysis). | 24-31 days |
Screening of Cardiac Abnormalities in the First Trimester of Pregnancy by Volumetric Acquisition

Study Overview
=================
Brief Summary
-----------------
Ultrasound is one of the most important tools in pregnancy both for its diagnostic capacity, but also because it is not invasive. For physiological pregnancy, the Italian guidelines provide for the execution of 3 ultrasounds: one in the first trimester (between 11 and 14 weeks), one in the second trimester (between 20 and 22 weeks) and one in the third (between 30 and 36 weeks). weeks). Screening for cardiac abnormalities is done during second trimester ultrasound, also called structural ultrasound. However, the development of three-dimensional (3D) sonography has represented a dramatic shift in obstetrics as it allows for the acquisition of a volume of data rather than conventional planar or 2D scans. This method has allowed considerable progress in the study of the fetus in the initial stages of development and has opened new windows in the knowledge of anatomical malformations at an early age. The possibility of detecting structural anomalies already during the first trimester of pregnancy allows, in fact, to provide the patient with additional time for counseling and for any genetic tests.

Official Title
-----------------
Screening of Cardiac Abnormalities in the First Trimester of Pregnancy by Volumetric Acquisition: an International Multicenter Study

Conditions
-----------------
Pregnancy, Ultrasound, Fetal Conditions, Cardiac Abnormalities

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients referred to the obstetric ultrasound clinic for the execution of the first trimester ultrasound between 11+0 and 13+6 weeks of gestation Exclusion Criteria: Less than 18 years old Multiple gestations Women with an altered state of consciousness, seriously ill, with mental handicaps;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardiac abnormalities found in the first trimester of pregnancy | Incidence of cardiac abnormalities found in the first trimester of pregnancy by 3D scan | Between 11+0 and 13+6 days of pregnancy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gestational age at delivery | Weeks of gestation at the moment of delivery | delivery | 
| Preterm birth rates |  | Less than 24, 28, 34 weeks gestation | 
| Birth weight | Weight of the baby at the time of delivery | delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, ultrasound, fetal abnormalities, Cardiac Abnormalities
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for patients with advanced NSCLC in the real world

Official Title
-----------------
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer

Conditions
-----------------
NSCLC

Intervention / Treatment
-----------------
* Drug: Camrelizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent and volunteered to join the study Aged >=18 years Patients with stage IIIb, IV, or relapsed non-small cell lung cancer diagnosed cytologically or histopathologically as EGFR/ALK- Eastern Cooperative Oncology Group (ECOG) performance status 0-1 At least one measurable lesion (according to RECIST 1.1) No prior systemic therapy for advanced/metastatic NSCLC contraception Exclusion Criteria: Those who are allergic to drug treatment； Patients who were also treated with other immunodrugs or therapies； Patients who are participating in other intervention studies； Patients with other malignant tumors at the same time； Pregnant or lactating women； The investigator did not consider the patients eligible to participate in the study under any other circumstances.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Camrelizumab|Cross - line treatment of Camrelizumab in non-small cell lung cancer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate (ORR) in second-line treatment of patients with non-small cell lung cancer based on Camrelizumab regimen | CR+PR | Up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Progression Free survival (PFS) in patients with non-small cell lung cancer based on first-line/second-line treatment with Camrelizumab | Progression free survival (PFS) according to RECIST 1.1 | Up to 36 months | 
| Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen | Evaluation of second progression-free survival (PFS2) in patients with non-small cell lung cancer based on Camrelizumab regimen | Up to 12 months | 
| OS | Overall survival | Up to 12 months | 
| To evaluate the safety of Camrelizumab based first/second line therapy in patients with non-small cell lung cancer | according to NCI-CTCAE version 5.0 | Up to 12 months |
Adolescent Knowledge of Their Medications

Study Overview
=================
Brief Summary
-----------------
Do adolescents know about their medications?

Official Title
-----------------
Medication Reconciliation List and Adolescent Functional Health Literacy

Conditions
-----------------
Subjects' Understanding of Prescribed Medications

Intervention / Treatment
-----------------
* Other: Counseling for subjects who do not know their medications


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adolescents between the ages of 12 and 23 who are able to answer questions regarding their prescribed medications (no receptive or expressive disability) Exclusion Criteria: Adolescents outside age range of 12 and 23 who have receptive and/or expressive disability

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 23 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjects' ability to identify name and purpose of medication. |  | Clinic visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRL, Adolescents, Health Literacy
Safety Assessment of Angioplasty Procedures

Study Overview
=================
Brief Summary
-----------------
Ischemic heart disease, or coronary heart disease, covers a set of pathologies due to insufficient oxygen supply to the myocardium due to the development of atherosclerosis in one or more coronary arteries. To evaluate the safety of angioplasty performed in patients operated on at La Rochelle Hospital, the rate of major adverse cardiac events (MACE) will be determined and compared with data from the literature.

Detailed Description
-----------------
The use of active stents for the treatment of coronary stenosis is currently the standard treatment in almost all types of coronary lesions. In percutaneous transluminal treatment of coronary lesions, balloon angioplasty and bare stents have not shown satisfactory results in the past. The so-called active drug-eluting balloon could represent a new therapeutic option for the treatment of de novo lesions.

Official Title
-----------------
Safety Assessment of Angioplasty Procedures

Conditions
-----------------
Angiospastic; Disorder

Intervention / Treatment
-----------------
* Device: Coronary angioplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Interventional revascularization of a coronary lesion, Member or beneficiary of a social security system, Informed of the study. Exclusion Criteria: Language barrier, Minor, Pregnant woman, Person under guardianship, Person deprived of his/her liberty, Refusal to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of major adverse cardiac events (MACE) | The primary endpoint is a composite endpoint that includes major adverse cardiac events defined as cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke (stroke) and revascularization of target lesion (TLR) within 12 months of surgery. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of major adverse cardiac events (MACE) | The secondary endpoint is a composite endpoint that includes major adverse cardiac events defined as cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke (stroke) and revascularization of target lesion (TLR) within 12 months of surgery. | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
drug eluting stent, Drug-coated balloon, Bare-Metal Stent, Revascularization